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Abstract
AIM: The aim of this study was to determine the correlation between interleukin-4 (IL-4) gene promoter polymorphisms 
with thyrotropin receptor antibody (TRAb) and transforming growth factor-β (TGF-β).
METHODS: This study was conducted from August 2015 until December 2015 in the internal medicine department 
in Dr. M. Djamil Hospital, Padang, West Sumatera, Indonesia. Graves’ disease was confirmed by measuring free 
thyroxine, thyroid-stimulating hormone, and TRAb. We examined that IL-4 promotor gene polymorphism was 
examined with a polymerase chain reaction. Graves’ disease serum patients will be used to check levels of TGFβ 
and TRAb antibodies using the enzyme-linked immunoassay method.
RESULTS: There are 15 patients in this study. The average of age in patients group is 40.87 (11.23) years. The 
number of female patients in this study is more than male patients, with the percentage of women are 73.3%, and 
men are 26.7%. The sequencing examination on IL-4 gene promoter resulted in 2 single nucleotide polymorphism 
motifs, which are rs2243250 and rs2070847. The mean TRAb level in wild type and mutant group is 6.77 (5.73) IU/L 
and 4.66 (3.91) IU/L, respectively. The mean TGF-β levels in wild type and mutant group are 1168.89 (438.91) pg/mL 
and 1114.79 (296.02) pg/mL, respectively. Statistical tests showed no association between IL-4 gene promoter 
polymorphisms with TRAb and TGF-β levels (p > 0.05).
CONCLUSION: There is no correlation between IL-4 gene promoter polymorphisms with TRAb and TGF-β.
Introduction
The most common cause of hyperthyroidism 
is Graves’ disease. Graves’ disease is a hyperthyroid 
state characterized by diffuse enlargement of the thyroid 
gland due to immunological causes. The immunological 
process that underlies Graves’ disease is the low 
clonal T cell regulator that functions to regulate the 
balance of T-helper (Th) 1 and Th2 cells in antibody 
production [1], [2], [3], [4], [5].
Interleukin (IL)-4 is part of cytokines that affect 
antibody production and allergic responses. Paschce 
et al. found various patterns of increased IL-2, IL-4, 
IL-10, and interferon-γ accumulation in thyroid surgery 
specimens from Graves patients. IL-4 is a cytokine 
produced by Th2 lymphocyte cells which have a role 
in the activation of B cells to form antibodies. IL-4 
stimulates the number of isotypes of immunoglobulin 
G-secreting cells (IgG3-SCs) associated with the 
severity of Graves’ disease and thyrotropin receptor 
antibody (TRAb) levels, while also changing to IgG1 
which can stimulate TRAb production effectively. 
Several studies have suggested a modest protective 
effect for the T allele of a promotor polymorphism in the 
IL-4 gene [6], [7], [8], [9], [10].
TRAb is an autoantibody that binds to thyroid-
stimulating hormone (TSH) receptors on the thyroid 
gland so that excessive thyroid hormone production 
occurs. Transforming growth factor (TGF)-β is one of 
the growth factors in tissue regeneration and repair. 
TGF-β is produced by various types of cells, including 
T lymphocytes. Several previous studies have 
found that levels of TRAb and TGF-β increase in the 
disease of Graves [6], [8]. The aim of this study was to 
determine the correlation between IL-4 gene promoter 
polymorphisms with TRAb and TGF-β.
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Methods
This study was conducted from August 
2015 until December 2015 in the internal medicine 
department in Dr. M. Djamil Hospital, Padang, West 
Sumatera, Indonesia. This study involved 15 patients 
with Graves’ disease. Graves’ disease was confirmed 
by measuring free thyroxine (FT4), TSH, and TRAb. 
Patients with other autoimmune hyperthyroid diseases, 
chronic infection, and malignancy were excluded. All 
blood samples have taken from these study participants 
for laboratory tests. All patients have provided signed 
consent. This research has received an ethical approval 
from the Ethics Committee of the Medical Faculty of 
Andalas University.
We examined that IL-4 promotor gene 
polymorphism was examined with polymerase chain 
reaction (PCR). Graves’ disease serum patients will 
be used to check levels of TGFβ and TRAb antibodies 
using the enzyme liked immunoassay method.
Results
There are 15 patients in this study. The average 
of age in patients group is 40.87 (11.23) years. The 
number of female patients in this study is more than 
male patients, with the percentage of women are 73.3% 
and men are 26.7%.
Mean FT4 level is 77.89 (72.77) pmol/l, 
mean serum TSH level is 0.07 (0.09) UIU/l, and mean 
TRAb level is 5.23 (4.35) IU/l. The reference range 
for these parameters is as follows: FT4 9 – 23 pmol/l, 
TSH 0.35 – 5.5 UIU/l, and TRAb <0.9 IU/l. Research’s 
subject characteristics are shown in Table 1.
Table 1: Baseline characteristics
Characteristics (n=15) Mean (SD) n (%)
Average Age (yo) 40.87 (11.23)
Sex
Male
Female
4 (26.7%)
11 (73.3%)
IL-4 (pg/ml) 27.59 (12.61)
IL-10 (pg/ml) 1.15 (1.06)
TGF-β (pg/ml) 1,129.21 (323.24)
TNF-α (pg/ml) 61.89 (9.54)
FT4 (pmol/l) 77.89 (72.77)
TSH (UIU/l) 0.07 (0.09)
TRAb (IU/l) 5.23 (4.35)
Goiter size (cm) 6.18 (3.91)
Sequencing examination on IL-4 gene 
promoter resulted in 2 single nucleotide polymorphism 
(SNP) motifs, which are rs2243250 and rs2070847. 
The allele that found in these SNP is CC (wild type), TT 
(mutant homozygote), and CT (mutant heterozygote). 
PCR results of direct DNA sequencing methods for SNP 
rs2243250 and rs2070847 in samples and controls are 
shown in Table 2.
Table 2: SNP motifs frequency in patients and controls
SNP motifs Allele Allele frequency p
Patient Control
f % f %
rs2243250 CC 4 26.7 4 26.7 0.693
TT 7 46.6 5 33.3
CT 4 26.7 6 40
rs2070847 CC 4 26.7 2 13.3 0.311
TT 7 46.6 5 33.3
CT 4 26.7 8 53.4
From Table 3, it can be seen that in the group 
that experienced mutations, the mean TRAb level 
was 6.77 (5.73) IU/L. This figure is higher than the 
average TRAb level in the group that did not experience 
mutations, which is 4.66 (3.91) IU/L. Statistical tests 
showed no relationship between IL-4 gene promoter 
polymorphisms and TRAb levels (p > 0.05).
Table 3: Correlation between interleukin-4 gene promoter 
polymorphisms SNP rs2243250 and rs2070847 with TRAb
Type Frequency Mean (SD)(IU/L) p
Wild type 4 6.77 (5.73) 0.514
Mutant 11 4.66 (3.91)
From Table 4, it can be seen that the mean 
TGF-β levels in the mutated group are 1168.89 (438.91) 
pg/mL. In the group that did not experience mutations, 
the average TGF-β level was 1114.79 (296.02) pg/
mL. Statistical tests showed no association between 
IL-4 gene promoter polymorphisms and TGF-β levels 
(p > 0.05).
Table 4. Correlation between interleukin-4 gene promoter 
polymorphisms SNP rs2243250 and rs2070847 with TGF-β
Type Frequency Mean (SD) (pg/mL) p
Wild type 4 1,168.89 (438.91) 0.786
Mutant 11 1,114.79 (296.02)
Discussion
Laurberg et al. (2014) conducted a study of 
208 Graves patients in Denmark with the aim to see the 
relationship of serum TRAb levels to the manifestations 
of Graves’ disease. The mean age of patients in the 
study was 45 years with an age range of 35–53 years. 
The average age of this study sample is smaller 
than the study conducted by Laurberg. The average 
age obtained in this study is in accordance with the 
Indonesian Society of Endocrinology Task Force on 
Thyroid Disease in 2012 which states that Graves’ 
disease appeared more frequently in the third and 
fourth decades. This statement is consistent with the 
basic characteristics of patients with Graves’ disease in 
other studies in different countries [5], [11].
According to Kahaly et al. (2018), Graves’ 
disease is more common in women than men and has a 
population prevalence of 1–1.5%. A higher percentage of 
events in women than men was found in studies conducted 
by several researchers and other research reports on 
Graves’ disease, which is an autoimmune disorder [12].
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Boot states that the diagnostic level of TRAb 
for Graves’ disease is more than 1.7 IU/L. In this 
study, the average TRAb level was 5.23 (4.35) IU/L. 
This means that all the samples in this study were 
laboratory-suffering from Graves’ disease. TRAb is an 
autoantibody that binds to TSH receptors on the thyroid 
gland so that excessive thyroid hormone production 
occurs [13]. TRAb levels in this study were found to be 
lower than the studies conducted by Bell in 2018. Bell 
et al. conducted a study by evaluating the diagnosis of 
Graves’ disease using TRAb. The average TRAb level 
obtained was 11.48 (1.46) IU/L [14].
Research conducted by Ylli et al. in Albania and 
Chen et al. in China who conducted a study of patients 
with Graves’ disease also obtained mean results of 
higher TRAb levels compared to this study, which was 
8.89 (3, respectively, 71) IU/L and 17.15 (12.88) IU/L 
[15], [16].
Hunt et al. conducted research on the 
relationship between IL-4-590C/T polymorphisms and 
autoimmune thyroid disease. This study found that the 
IL-4-590C/T genotype had a protective effect on the 
development of autoimmune thyroid disease, especially 
Graves’ disease. However, in this study, no significant 
polymorphism (including IL-4-590 polymorphism) was 
detected with the age of onset, size of thyroid gland, 
thyroid peroxidase titer or thyroglobulin antibody, thyroid 
eye disease, or the presence of other autoimmune 
diseases [17].
In this study, there was no correlation between 
IL-4 gene polymorphisms and TRAb levels. In the 
group that did not experience a gene mutation, the 
average TRAb value was 6.77, while in the group 
that experienced a gene mutation, the average TRAb 
value was 4.66. From the analysis of the data, it was 
found that there was no correlation between IL-4 gene 
mutations (polymorphisms) with TRAb levels of Graves’ 
patients.
Khalilzadeh et al. (2009) investigated 
the relationship between IL-4, IL-10, and TGFβ 
polymorphisms in Graves’ disease. The number of 
samples of 247 people consisting of 107 patients with 
Graves’ disease and 140 controls healthy patients. The 
results are Graves’ disease more often found in the IL-4-
1098G allele and GG genotype. In 68 Graves’ disease 
patients, there was an increase in TGF-β in the allele 
+ 869C with CC genotype. Therefore, there is a very 
significant relationship between polymorphisms of anti-
inflammatory cytokine genes and Graves’ disease [18].
In this study, there was no correlation between 
IL-4 gene polymorphisms and TGF-β levels. In the wild 
type group, the mean TGF-β value was 1168.89 while 
in the group that had a gene mutation, the mean TGF-β 
value was 1114.79. From the analysis of the data, it was 
found that there was no correlation between IL-4 gene 
mutations polymorphisms with TGF-β levels in Graves’ 
patients with p = 0.786.
In this study, the average levels of TGF-β 
Graves’ disease were found in 1129.21 (323.24) pg/ml, 
while the research conducted by Elvira et al. about the 
relationship between polymorphism of the T-Regulator 
FOXP3 gene promoter with TGF-β in Graves’ disease 
patients found that the average levels TGF-β in Graves’ 
disease were higher than in the control group which 
was 1030.01 (277.64) ng/ml, while the control group 
was 889.72 (37.86) ng/ml [19].
Kotajima et al. (2010) conducted a study 
on the effect of thyroid hormone and TGF-β on the 
concentration of cystatin C. This study was conducted in 
patients with Graves’ disease and hypothyroidism who 
were never given drugs. In this study, they found a very 
significant increase in TGF-β level in Graves’ disease 
compared to the control group, whereas hypothyroid 
patients TGF-β level were lower than in the control 
group. In the control group consists of 25 samples, 
TGF-β level is 11.7 (3.6) ng/ml, while Graves’ disease 
consists of 33 patients, TGF-β level is 18.3 (5.1) ng/ml, 
hypothyroid patients consist of 8 patients, and TGF-β 
level is 8.8 (4.2) ng/ml [20].
Conclusion
It can be concluded that with a limited number of 
subjects in this study, there is no correlation between IL-4 
gene promoter polymorphisms with TRAb and TGF-β.
References
1. Decroli E, Elvira D, Aprilia A. The profile of thyrotropin-releasing 
hormone, T-regulator, and interleukin-4 of untreated graves’ 
disease in Indonesia. Asian J Pharm Clin Res. 2020;13(7):57-9.
https://doi.org/10.22159/ajpcr.2020.v13i7.37731
2. Davies T, Laurberg P, Bahn R. Hyperthyroid disorders. In: 
Melmed S, Polonsky K, Larsen R, Kronenberg H, editors. 
Williams Textbook of Endocrinology. 13th ed. Philadelphia, PA: 
Elsevier; 2011. p. 369-415.
3. Lillevang-Johansen M, Abrahamsen B, Jorgensen H, Brix T, 
Hegedus L. Excess mortality in treated and untreated 
hyperthyroidism is related to cumulative periods of low serum 
TSH. J Clin Endocrinol Metab. 2017;102(7):2301-9. https://doi.
org/10.1210/jc.2017-0016
 PMid:28368540
4. Liu J, Fu J, Xu Y, Wang G. Antithyroid drug therapy for graves’ 
disease and implications for recurrence. Int J Endocrinol. 
2017;2017:3813540. https://doi.org/10.1155/2017/3813540
 PMid:28529524
5. The Indonesian Society of Endocrinology. Indonesian clinical 
practice guidelines for hyperthyroidism. J ASEAN Fed Endocr 
Soc. 2012;27(1):34-9. https://doi.org/10.15605/jafes.027.01.05
6. Wang PW, Chen IY, Juo SH, His E, Liu RT, Hsieh CJ. Genotype 
and phenotype predictors of relapse of graves’ disease after 
A - Basic Sciences Immunology
796 https://www.id-press.eu/mjms/index
antithyroid drug withdrawal. Eur Thyroid J. 2012;1(4):251-8. 
https://doi.org/10.1159/00034262
 PMid:24783027
7. Decroli E, Elvira D, Aprilia A. The effect of thionamide to 
TRH, TSH, IL-4, T-reg, and anti-TPO in graves’ disease. 
Indones J Pharm. 2019;30(2):122-7. https://doi.org/10.14499/
indonesianjpharm30iss2pp122-127
8. Decroli E, Manaf A, Syahbuddin S. Immunologic and hormonal 
effects of propylthiouracil treatment using maintenance dose in 
graves’ disease. Acta Med Indones. 2014;46(4):314-9. 
 PMid:25633548
9. Elvira D, Darwin E. Role of pro-inflammatory and regulatory 
cytokines in pathogenesis of graves’ disease in association with 
autoantibody thyroid and regulatory FoxP3 T-cells. Int J Med 
Health Sci. 2017;11(3):69-72.
10. Elvira D. The role of T-regulatory expression in autoimmune thyroid 
disease and its association with thyroid antibody. J Autoimmune 
Dis. 2016;2(2):19. https://doi.org/10.21767/2471-8513.100019
11. Laurberg P, Nygaard B, Andersen S, Carle A, Karmisholt J, 
Kerjbjerg A, et al. Association between TSH-receptor 
autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 
patients included in the remission induction and sustenance 
in graves’ disease study. J Thyroid Res. 2014;2014:165487. 
https://doi.org/10.1155/2014/165487
 PMid:24696787
12. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, 
Pearce SH. 2018 European thyroid association guideline for 
the management of graves’ hyperthyroidism. Eur Thyroid J. 
2018;7(4):167-86. https://doi.org/10.1159/000490384
 PMid:30283735
13. Boot C. Role of TSH Receptor antibodies in the diagnosis of 
graves’ disease. Clin Lab. 2016;2016:1-7.
14. Bell L, Hunter A, Kyriacou A, Mukherjee A, Syed A. Clinical 
diagnosis of graves’ or non-graves’ hyperthyroidism compared to 
TSH receptor antibody test. Endocr Connect. 2018;7(4):504-10. 
https://doi.org/10.1530/ec-18-0082
 PMid:29531156
15. Ylli Z, Dyrmishi B, Puca E, Husi G, Kolici E, Kapia M, et al. 
TSH receptor antibody measurement in the diagnosis of 
graves’disease. Endocr Abstr. 2011;26:P433.
16. Chen X, Huang F, Qi Y, Zhou M, Yin Q, Peng Y, et al. Serum 
and thyroid level of let-7b and their correlation with TRAb in 
graves’ disease. J Transl Med. 2018;16(1):188-98. https://doi.
org/10.1186/s12967-018-1565-9
 PMid:29976201
17. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. 
Cytokine gene polymorphisms in autoimmune thyroid disease. 
J Clin Endocrinol Metab. 2000;85(5):1984-8. https://doi.
org/10.1210/jcem.85.5.6588
 PMid:10843185
18. Khalilzadeh O, Anvari M, Momen-Heravi F, Esteghamati A, 
Rashidi A, Mahmoudi M, et al. Gene polymorphisms of 
interleukin-4, interleukin-10 and transforming growth factor-beta 
in graves’ disease. Clin Exp Med. 2010;10(2):123-8. https://doi.
org/10.1007/s10238-009-0078-5
 PMid:19882211
19. Elvira D. Correlation between polymorphisms of foxp3 
T-regulatory promotor gene with TGF-Β in patients with graves’ 
disease. Asian J Pharm Clin Res. 2020;13(7):133-5. https://doi.
org/10.22159/ajpcr.2020.v13i7.37717
20. Kotajima N, Yanagawa Y, Aoki T, Tsunekawa K, Morimura T, 
Ogiwara T, et al. Influence of thyroid hormones and 
transforming growth factor-β1 on cystatin C concentration. 
J Int Med Res. 2010;38(4):1365-73. https://doi.
org/10.1177/147323001003800418
 PMid:20926009
